{"id":"active-comparator-aspirin-clopidogrel","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Bleeding (major and minor)"},{"rate":"1-3","effect":"Gastrointestinal bleeding"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"0.5-1","effect":"Intracranial hemorrhage"},{"rate":"0.02-0.05","effect":"Thrombotic thrombocytopenic purpura (TTP)"}]},"_chembl":{"chemblId":"CHEMBL1771","moleculeType":"Small molecule","molecularWeight":"321.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet activation. Clopidogrel is a P2Y12 adenosine diphosphate receptor antagonist that prevents platelet aggregation. Combined, they provide dual antiplatelet therapy with complementary mechanisms to reduce clot formation.","oneSentence":"Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent thrombotic events.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:21.035Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome"},{"name":"Secondary prevention after myocardial infarction"},{"name":"Stroke prevention in patients with recent ischemic stroke or transient ischemic attack"},{"name":"Prevention of stent thrombosis after percutaneous coronary intervention"}]},"trialDetails":[{"nctId":"NCT07007143","phase":"PHASE4","title":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-07-31","conditions":"Mitral Regurgitation","enrollment":1032},{"nctId":"NCT06901466","phase":"PHASE4","title":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-06-13","conditions":"Mitral Regurgitation","enrollment":880},{"nctId":"NCT03729401","phase":"PHASE4","title":"Personalization of Long-Term Antiplatelet Therapy - RAPID EXTEND","status":"SUSPENDED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2019-08-22","conditions":"Coronary Artery Disease, Myocardial Infarction","enrollment":390},{"nctId":"NCT04738097","phase":"PHASE3","title":"Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2021-08-08","conditions":"Ischemic Stroke, Transient Ischemic Attack","enrollment":90},{"nctId":"NCT01813435","phase":"PHASE3","title":"GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2013-07-01","conditions":"Coronary Artery Disease (CAD)","enrollment":15991},{"nctId":"NCT05238610","phase":"","title":"Prospective Registry of Elderly ESUS With PFO","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2022-01-17","conditions":"Embolic Stroke of Undetermined Source","enrollment":1200},{"nctId":"NCT03273322","phase":"PHASE2, PHASE3","title":"Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-09-13","conditions":"Atrial Fibrillation, Atrial Appendage, Hemorrhage","enrollment":105},{"nctId":"NCT02164864","phase":"PHASE3","title":"Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-07-22","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2725},{"nctId":"NCT03068845","phase":"PHASE3","title":"Arteriovenous Fistula: Conventional Angioplasty vs Drug Eluting Balloon-assisted Maturation Intervention Clinical Trial","status":"UNKNOWN","sponsor":"Singapore General Hospital","startDate":"2017-06","conditions":"Stenosis of Arteriovenous Dialysis Fistula","enrollment":124},{"nctId":"NCT00557921","phase":"PHASE3","title":"Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)","status":"TERMINATED","sponsor":"Cogentus Pharmaceuticals","startDate":"2007-12","conditions":"Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease","enrollment":5000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":76,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Active Comparator: Aspirin+Clopidogrel","genericName":"Active Comparator: Aspirin+Clopidogrel","companyName":"Chinese Academy of Medical Sciences, Fuwai Hospital","companyId":"chinese-academy-of-medical-sciences-fuwai-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent thrombotic events. Used for Acute coronary syndrome, Secondary prevention after myocardial infarction, Stroke prevention in patients with recent ischemic stroke or transient ischemic attack.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}